Onco-endocrinology
PROJECTS:
- Analysis of hormonal and metabolic factors that affect the risk of cancer development, course of disease and response to treatment.
- Investigation of the role of diabetes mellitus, heterogeneity of the obesity, the state of adipose tissue in the mechanism of occurrence and clinical peculiarities of the oncological diseases.
- Investigation of the relationship between pituitary-steroid regulation disorders and the characteristics of the tumor process in prostate and breast cancer.
- Hormonal and metabolic disorders associated with conservative antitumor therapy and the development of the new approaches for their correction.
- Investigation of the role of hormonal and metabolic factors in the development of genotoxic disorders reflected by the degree of DNA damage in lymphocytes.
ACHIEVEMENTS:
1. "Petrovsky" diagnostic score or Petrov Thyroid Cancer Score (PTCS)
In order to improve the thyroid cancer diagnostics, the Petrovsky diagnostic score or Petrov Thyroid Cancer Score (PTCS) was developed (Belyaev A.M. et al 2018, 2019), which includes an assessment of the most significant diagnostic parameters. It has been shown that with PCTS up to 5.0 inclusive, the diagnostic sensitivity is 80.2%, the specificity is 89.3%, and the diagnostic accuracy is 83.7%, which indicates the reliability of the method used.
2. Three-week thyroglobulin test
“Three-week thyroglobulin test” was developed with the purpose of monitoring the condition of patients underwent extirpation of the thyroid gland. The test is based on assessment of the level of blood thyroglobulin 3 weeks after surgery. A concentration of this marker exceeding 2 ng / ml indicates a high risk of disease recurrence.
3. The "DNA comet" method
A method of assessing the degree of DNA damage in lymphocytes (the “DNA comet method”) has been developed. It allows to determine the genotoxic effect of the hormonal and metabolic background, tumor process, and therapy. It has been shown that the degree of DNA damage can serve as a criterion for prediction the course of the disease and its sensitivity to treatment.
HEAD OF THE LAB:
RESEACH STAFF:
“Onco-endocrinology” team
Berstein L.M., MD., prof.
Tsyrlina E.V., MD., PhD.
Vasiliev D.A., MD., PhD.
Kovalenko I.M., MD., PhD
“Nanovesicles-related technology” team
Nazarova I.V.
Nikifiriva N.S.
Slyusarenko M.A.
“Methods of miRNA analysis” team:
Sidina E.I.
Knyazeva M.S.
Zabegina L.M.
Malysheva S.A.